![Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence - Kamal Hamed, Laurie Debonnett, 2017 Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence - Kamal Hamed, Laurie Debonnett, 2017](https://journals.sagepub.com/cms/10.1177/1753465817691239/asset/images/large/10.1177_1753465817691239-fig1.jpeg)
Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence - Kamal Hamed, Laurie Debonnett, 2017
![Pharmaceutics | Free Full-Text | Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler Pharmaceutics | Free Full-Text | Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-01528/article_deploy/html/images/pharmaceutics-13-01528-g001.png)
Pharmaceutics | Free Full-Text | Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler
![FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US | Fierce Pharma FDA approves Novartis TOBI® Podhaler™ for certain cystic fibrosis patients, the first and only dry powder inhaled antibacterial in US | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=250,h=165,g=0.5x0.5,f=auto,fit=crop/https://qtxasset.com/quartz/qcloud5/media/image/OZEMPIC2.jpg?VersionId=q.L1sWRGiHcHLxxysDKFYspYgame.z2q)